Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report.

@article{Novick2017TenofovirAN,
  title={Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report.},
  author={Tessa K. Novick and Michael James Choi and Avi Z Rosenberg and Blaithin A McMahon and Derek Fine and Mohamed G. Atta},
  journal={Medicine},
  year={2017},
  volume={96 36},
  pages={e8046}
}
RATIONALE Tenofovir alafenamide (TAF) is novel prodrug of Tenofovir, a nucleotide reverse transcriptase inhibitor. TAF is less nephrotoxic than its predecessor prodrug, tenofovir disoproxil fumarate (TDF). Tenofovir causes mitochondrial dysfunction and tubular injury when there is elevated accumulation in proximal tubule cells. TAF's unique pharmacokinetic profile enables provision of lower required doses for antiviral efficacy. Lower concentrations reach renal tubules minimizing intracellular… CONTINUE READING